Table 3

Association of HLA-I supertypes with overall survival of NSCLC patients treated with anti-PD1/PDL1

HLA-I supertypeFrequency N (%)HR (95% CI)P value
A2438 (23.6)1.34 (0.74 to 2.41)0.295
A0171 (44.1)0.95 (0.57 to 1.57)0.834
A02 80 (49.7) 0.56 (0.34 to 0.93) 0.023
A0384 (52.2)1.27 (0.77 to 2.08)0.356
B5813 (8.1)0.98 (0.40 to 2.43)0.966
B6230 (18.6)1.55 (0.80 to 3.00)0.137
B2732 (19.9)0.91 (0.55 to 1.49)0.075
B4490 (55.9)0.83 (0.50 to 1.38)0.470
B0775 (46.6)0.91 (0.55 to 1.49)0.705
B0837 (23)1.11 (0.60 to 2.07)0.724
A01/A2413 (8.1)1.29 (0.51 to 3.30)0.548
  • HLA, human leukocyte antigen; ;NSCLC, non-small cell lung cancer; PD1/PDL1, programmed cell death protein-1/programmed death ligand 1.